External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?
about
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusAre statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in FinlandThe rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010.Making randomised trials more efficient: report of the first meeting to discuss the Trial Forge platformRegression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis.Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysisSimilarities and differences between patients included and excluded from a randomized clinical trial of vitamin D supplementation for improving glucose tolerance in prediabetes: interpreting broader applicability.A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial resultsLEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ.Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific ProgrammeTrends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015.Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in IndiaGuidance on guidelines: Understanding the evidence on the uptake of health care guidelines.Generalizability analysis for clinical trials: a simulation study.Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration.Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study.Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes.Optimization of home treatment in haemophilia: effects of transmural support by a haemophilia nurse on adherence and quality of life.Clinical drug trials in general practice: how well are external validity issues reported?Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains.Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.
P2860
Q24186667-52808BA2-F05D-4C28-9D7F-BC572CACC5B3Q24202505-CF64FF2A-0FB0-4092-9092-3B92BBEFB808Q33795544-429977AF-FCD0-4D38-92D1-5A078A898F69Q35562646-18B581DF-BD9E-4872-B53A-1EF9110A5470Q35653223-E7CAE83C-6704-423B-A9C1-0175DDA558D8Q35701348-1DC3AA4E-FBAC-44E3-AA9B-B4B926989F42Q35830021-251C718B-4765-4A20-A2B2-0625F0A88748Q35853553-681F14F2-47A7-4500-8135-D321B31CEF0AQ36246590-6EA27515-7187-43E5-91CE-03C64F729E39Q36965468-B91F27AC-3859-4C29-9148-6D8EA18D1475Q37236940-FB59C43F-39F1-4273-AB21-481034C70336Q37397867-9E4A1409-6BAA-4D80-A7E7-920EC9AE6A56Q37456636-5383C387-C51C-4F3F-9223-3B509570E08CQ39169793-F2C30A4A-E305-4A57-923F-A0C0F0F6C716Q39216144-74CB8DED-3B8A-4D31-BACC-864DB4126FB3Q40363203-741F66A7-38EC-4583-8703-D2183C453D93Q41570665-DC0582D3-0BCD-47C7-A58F-B5F08ACCAC9AQ41685405-AEDA0F03-6A7C-4A56-A7B9-572A2F6FD7F0Q42365040-34500445-6464-4B8E-819F-2B092BAF593EQ42371337-B637E908-9E13-43B7-B726-3F5457BBCD60Q45861239-B6F2B7C8-0FCA-4889-B38D-EE85CB2FDDB4Q47101167-DFCF5F25-4F6E-4536-8464-B2227AA4FF19Q47168576-AB0ED670-37A5-4B36-AFA9-350B08570659Q54940707-23D6968D-EADF-41C1-A500-6C2DFB505797
P2860
External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
External validity of randomize ...... presentative are participants?
@en
type
label
External validity of randomize ...... presentative are participants?
@en
prefLabel
External validity of randomize ...... presentative are participants?
@en
P2093
P2860
P50
P356
P1433
P1476
External validity of randomize ...... presentative are participants?
@en
P2093
C Saunders
J A McKnight
J J Walker
Scottish Diabetes Research Network Epidemiology Group
P2860
P304
P356
10.1111/DME.12047
P577
2013-03-01T00:00:00Z